Regeneron Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Regeneron Pharmaceuticals Inc 公司

公司简介

公司代码REGN

公司名称Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

成立日期1988

CEODr. Leonard S. Schleifer, M.D., Ph.D

员工数量15106

证券类型Ordinary Share

年结日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10591

电话17813705000

网址https://www.regeneron.com/

公司代码REGN

上市日期Apr 02, 1991

成立日期1988

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.44K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.39K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Mr. George L. Sing

Independent Director

29.90K

+0.56%

Mr. Arthur F. (Art) Ryan

Independent Director

17.67K

+0.95%

Mr. Christopher R. Fenimore

Chief Financial Officer, Senior Vice President - Finance

16.35K

+6.24%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.36K

+9.94%

名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.44K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.39K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

收入明细

单位: USD更新时间: 3月5日周三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

EYLEA

4.76B

33.56%

Sanofi

4.53B

31.90%

Bayer

1.49B

10.55%

EYLEA HD

1.20B

8.45%

Libtayo

787.30M

5.54%

Other

1.41B

9.97%

暂无数据

业务

地区

业务USD

名称

营收

占比

EYLEA

4.76B

33.56%

Sanofi

4.53B

31.90%

Bayer

1.49B

10.55%

EYLEA HD

1.20B

8.45%

Libtayo

787.30M

5.54%

Other

1.41B

9.97%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.29%

JP Morgan Asset Management

4.87%

State Street Global Advisors (US)

4.49%

Other

69.32%

持股股东

股东统计

占比

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.29%

JP Morgan Asset Management

4.87%

State Street Global Advisors (US)

4.49%

Other

69.32%

股东类型

股东统计

占比

Investment Advisor

47.61%

Investment Advisor/Hedge Fund

32.88%

Research Firm

2.70%

Pension Fund

2.59%

Bank and Trust

2.16%

Hedge Fund

2.09%

Individual Investor

1.66%

Sovereign Wealth Fund

1.14%

Holding Company

0.08%

Other

7.04%

机构持股

更新时间: 1月19日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q1

2499

99.91M

92.94%

-662.36K

2024Q4

2581

100.16M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.76M

92.44%

+388.23K

2023Q4

2406

98.49M

91.94%

-617.05K

2023Q3

2358

98.79M

92.52%

-1.70M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

2022Q4

2333

99.77M

93.16%

-1.61M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

9.23M

8.59%

-32.54K

-0.35%

Dec 31, 2024

Fidelity Management & Research Company LLC

7.97M

7.41%

-2.07M

-20.68%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.69M

5.29%

+193.70K

+3.52%

Dec 31, 2024

JP Morgan Asset Management

5.24M

4.87%

-524.96K

-9.10%

Dec 31, 2024

State Street Global Advisors (US)

4.83M

4.49%

-70.16K

-1.43%

Dec 31, 2024

Capital International Investors

4.73M

4.4%

+1.39M

+41.55%

Dec 31, 2024

Capital World Investors

2.77M

2.58%

-1.51M

-35.34%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.42M

2.25%

+155.36K

+6.83%

Dec 31, 2024

Dodge & Cox

2.32M

2.15%

+9.38K

+0.40%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

2.19M

2.02%

+36.58K

+1.69%

Dec 31, 2024

持股ETF

更新时间: 15 小时前

机构名称

占比

Future Fund Active ETF

9.96%

ProShares Ultra Nasdaq Biotechnology

7.13%

Invesco Nasdaq Biotechnology ETF

6.75%

VanEck Biotech ETF

6.03%

iShares Biotechnology ETF

5.81%

Tema Oncology ETF

4.8%

Invesco Biotechnology & Genome ETF

4.36%

Tema Neuroscience and Mental Health ETF

4.03%

Franklin Genomic Advancements ETF

4.03%

iShares Genomics Immunology and Healthcare ETF

3.33%

Future Fund Active ETF

占比9.96%

ProShares Ultra Nasdaq Biotechnology

占比7.13%

Invesco Nasdaq Biotechnology ETF

占比6.75%

VanEck Biotech ETF

占比6.03%

iShares Biotechnology ETF

占比5.81%

Tema Oncology ETF

占比4.8%

Invesco Biotechnology & Genome ETF

占比4.36%

Tema Neuroscience and Mental Health ETF

占比4.03%

Franklin Genomic Advancements ETF

占比4.03%

iShares Genomics Immunology and Healthcare ETF

占比3.33%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Regeneron Pharmaceuticals Inc

689.060USD

Regeneron Pharmaceuticals Inc

689.060

概览

公司